![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
GF Reidy, I Mehta and M Murray
Department of Medicine, Westmead Hospital, NSW, Australia.
The anti-parkinsonian agent orphenadrine has been shown to form an in vitro metabolic intermediate (MI) complex in hepatic microsomes isolated from phenobarbital (PB)-treated rats. The present study was undertaken to assess the cytochrome P-450 isozyme specificity of inhibition and MI complexation. Spectral studies with untreated and PB- induced rat hepatic microsomes confirmed earlier reports on the selectivity of P-450 complexation by orphenadrine; MI complex formation was only observed with PB-induced microsomes. Inhibition studies with the P-450 substrates androst-4-ene-3,17-dione (androstenedione) and 7- pentoxyresorufin revealed selective inhibition of P-450 PB-B/D- associated monooxygenase activity. Thus, in microsomes from untreated male rats, orphenadrine failed to significantly inhibit (less than 50% inhibition up to a concentration of 300 microM) any of the major pathways of P-450-associated androstenedione metabolism. Preincubation of these microsomal fractions with orphenadrine and NADPH was not associated with increased inhibition of androstenedione metabolism. However, in PB-induced microsomes, P-450 PB-B/D-specific androstenedione 16 beta-hydroxylase activity was significantly and selectively inhibited (IC50 = 90 microM). Preincubation of orphenadrine with NADPH-supplemented PB-induced microsomes for 2, 4, or 8 min before androstenedione addition resulted in increased inhibition toward 16 beta-hydroxylase activity, lowering the observed IC50 to 6.6, 0.47, and 0.06 microM), respectively. Preincubation did not affect the selectivity of inhibition. In the absence of preincubation, orphenadrine appeared to be a potent mixed (competitive/noncompetitive)- type inhibitor of P-450 PB-B/D-associated pentoxyresorufin O- depentylation (Ki = 3.8 microM). Preincubation of orphenadrine with NADPH-supplemented microsomal fractions for 4 min resulted in a 30-fold lowering of the apparent inhibitor constant (Ki = 0.13 microM) and a change in the apparent inhibition kinetics to noncompetitive. Treatment of rats with orphenadrine (75 mg/kg/day intraperitoneally for 3 days) was associated with a 2-fold induction of total hepatic P-450, a 5- and 2.4-fold induction of androstenedione 16 beta- and 6 beta-hydroxylase activity, respectively, and formation of an orphenadrine-P-450 MI complex. Western blots of orphenadrine-induced microsomes revealed a 20- fold increase in P-450 PB-B/D-immunoreactive protein.(ABSTRACT TRUNCATED AT 400 WORDS)
This article has been cited by other articles:
|
|
 |
|
  H. Yamanaka, M. Nakajima, T. Fukami, H. Sakai, A. Nakamura, M. Katoh, M. Takamiya, Y. Aoki, and T. Yokoi CYP2A6 AND CYP2B6 ARE INVOLVED IN NORNICOTINE FORMATION FROM NICOTINE IN HUMANS: INTERINDIVIDUAL DIFFERENCES IN THESE CONTRIBUTIONS Drug Metab. Dispos., December 1, 2005; 33(12): 1811 - 1818. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. J. Smith, J. R. Bend, L. L. Bedard, K. R. Reid, D. Petsikas, and T. E. Massey BIOTRANSFORMATION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE (NNK) IN PERIPHERAL HUMAN LUNG MICROSOMES Drug Metab. Dispos., September 1, 2003; 31(9): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, Y. Ramamoorthy, R. F. Tyndale, and E. M. Sellers INTERACTION OF BUPRENORPHINE AND ITS METABOLITE NORBUPRENORPHINE WITH CYTOCHROMES P450 IN VITRO Drug Metab. Dispos., June 1, 2003; 31(6): 768 - 772. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Chen, W. Chen, L.-S. Gan, and A. E. Mutlib Metabolism of (S)-5,6-Difluoro-4-cyclopropylethynyl-4-trifluoromethyl-3, 4-dihydro-2(1H)-quinazolinone, a Non-Nucleoside Reverse Transcriptase Inhibitor, in Human Liver Microsomes. Metabolic Activation and Enzyme Kinetics Drug Metab. Dispos., January 1, 2003; 31(1): 122 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Hijazi and R. Boulieu Contribution of CYP3A4, CYP2B6, and CYP2C9 Isoforms to N-Demethylation of Ketamine in Human Liver Microsomes Drug Metab. Dispos., July 1, 2002; 30(7): 853 - 858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Morioka, M. Otsu, S. Naito, and T. Imai Phosphonate O-Deethylation of [4-(4-Bromo-2-Cyano-Phenylcarbamoyl) Benzyl]-Phosphonic Acid Diethyl Ester, a Lipoprotein Lipase-Promoting Agent, Catalyzed by Cytochrome P450 2C8 and 3A4 in Human Liver Microsomes Drug Metab. Dispos., March 1, 2002; 30(3): 301 - 306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Zhang, Y. Ramamoorthy, T. Kilicarslan, H. Nolte, R. F. Tyndale, and E. M. Sellers Inhibition of Cytochromes P450 by Antifungal Imidazole Derivatives Drug Metab. Dispos., March 1, 2002; 30(3): 314 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Hamaoka, Y. Oda, I. Hase, and A. Asada Cytochrome P4502B6 and 2C9 do not metabolize midazolam: kinetic analysis and inhibition study with monoclonal antibodies Br. J. Anaesth., April 1, 2001; 86(4): 540 - 544. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Komatsu, H. Yamazaki, S. Asahi, E. M. J. Gillam, F. P. Guengerich, M. Nakajima, and T. Yokoi Formation of A Dihydroxy Metabolite of Phenytoin in Human Liver Microsomes/cytosol: Roles of Cytochromes P450 2c9, 2c19, and 3a4 Drug Metab. Dispos., November 1, 2000; 28(11): 1361 - 1368. [Abstract] [Full Text]
|
|
|
|
|
|
K. Kobayashi, S. Abe, M. Nakajima, N. Shimada, M. Tani, K. Chiba, and T. Yamamoto Role of Human CYP2B6 in S-Mephobarbital N-Demethylation Drug Metab. Dispos., December 1, 1999; 27(12): 1429 - 1433. [Abstract] [Full Text]
|
|
|
|
|
|
C. P. Granvil, A. Madan, M. Sharkawi, A. Parkinson, and I. W. Wainer Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver Microsomes Drug Metab. Dispos., April 1, 1999; 27(4): 533 - 541. [Abstract] [Full Text]
|
|
|
|
|
|
T. Hashizume, M. Mise, Y. Terauchi, L. O, T. Fujii, H. Miyazaki, and T. Inaba N-Dealkylation and Hydroxylation of Ebastine by Human Liver Cytochrome P450 Drug Metab. Dispos., June 1, 1998; 26(6): 566 - 571. [Abstract] [Full Text]
|
|
|
|
|
|
S. H. Lee and J. T. Slattery Cytochrome P450 Isozymes Involved in Lisofylline Metabolism to Pentoxifylline in Human Liver Microsomes Drug Metab. Dispos., December 1, 1997; 25(12): 1354 - 1358. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Guo, S. Raeissi, R. B. White, and J. C. Stevens Orphenadrine and Methimazole Inhibit Multiple Cytochrome P450 Enzymes in Human Liver Microsomes Drug Metab. Dispos., March 1, 1997; 25(3): 390 - 393. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
